KRAS and colorectal carcinoma: In summary, under controlled conditions in these studies of first-line treatment in metastatic CRC, KRAS mutation was found to be a predictive marker for lack of response to cetuximab treatment, either alone or in combination with irinotecan- or oxaliplatin-based chemotherapies.